• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Arcus Biosciences Inc (NY: RCUS )

    15.29 -0.27 (-1.74%)
    Official Closing Price Updated: 7:00 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Arcus Biosciences Inc

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer
    From Arcus Biosciences
    Via Business Wire
    Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting
    From Arcus Biosciences
    Via Business Wire
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    Unveiling 5 Analyst Insights On Arcus Biosciences
    Via Benzinga
    Where Arcus Biosciences Stands With Analysts
    Via Benzinga
    Demystifying Arcus Biosciences: Insights From 4 Analyst Reviews
    Via Benzinga
    First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer
    From Arcus Biosciences
    Via Business Wire
    Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update
    From Arcus Biosciences
    Via Business Wire
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    Breaking Down Arcus Biosciences: 4 Analysts Share Their Views
    Via Benzinga
    Cracking The Code: Understanding Analyst Reviews For Arcus Biosciences
    Via Benzinga
    Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium
    From Arcus Biosciences
    Via Business Wire
    This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
    Via Benzinga
    Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma
    From Arcus Biosciences
    Via Business Wire
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital
    From Arcus Biosciences
    Via Business Wire
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    Arcus Biosciences to Participate in Two Upcoming Investor Conferences
    From Arcus Biosciences
    Via Business Wire
    RCUS Stock Earnings: Arcus Biosciences Beats EPS, Beats Revenue for Q2 2024
    RCUS stock results show that Arcus Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update
    From Arcus Biosciences
    Via Business Wire
    Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update
    From Arcus Biosciences
    Via Business Wire
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia
    From Arcus Biosciences
    Via Business Wire
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers
    From Arcus Biosciences
    Via Business Wire
    Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
    From Arcus Biosciences
    Via Business Wire
    After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal Cancer Studies
    Gilead Sciences and Arcus Biosciences report sustained efficacy and safety in the Phase 2 EDGE-Gastric study for upper GI cancers, showing improved progression-free survival and objective response... 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.